Alzheimer's disease: a general introduction and pathomechanism
VH Finder - Journal of Alzheimer's disease, 2010 - content.iospress.com
Alzheimer's disease (AD) is the most common form of dementia, which affects more than 35
million people worldwide with increasing tendency. Satisfying therapies and prevention are …
million people worldwide with increasing tendency. Satisfying therapies and prevention are …
Alzheimer's disease therapeutic approaches
M Revi - GeNeDis 2018: Genetics and Neurodegeneration, 2020 - Springer
Alzheimer's disease (AD) was first described and diagnosed by Dr. Alois Alzheimer in 1906
(Hippius and Neundorfer, Dialogues Clin Neurosc 5: 101–108, 2003). According to World …
(Hippius and Neundorfer, Dialogues Clin Neurosc 5: 101–108, 2003). According to World …
Current and future treatments for Alzheimer's disease
KG Yiannopoulou… - Therapeutic advances in …, 2013 - journals.sagepub.com
Alzheimer's dementia (AD) is increasingly being recognized as one of the most important
medical and social problems in older people in industrialized and non-industrialized …
medical and social problems in older people in industrialized and non-industrialized …
New approaches for the treatment of Alzheimer's disease
Alzheimer's disease (AD) is the most prevalent chronic neurodegenerative disease. Current
approved therapies are symptomatic treatments having some effect on cognitive function …
approved therapies are symptomatic treatments having some effect on cognitive function …
The present and future of pharmacotherapy of Alzheimer's disease: A comprehensive review
Alzheimer's disease (AD) is a generalized term used for the loss in memory and other
intellectual abilities on levels serious enough to interfere with daily life. It accounts for 60 …
intellectual abilities on levels serious enough to interfere with daily life. It accounts for 60 …
Current perspectives on pharmacotherapy of Alzheimer's disease
K Chopra, S Misra, A Kuhad - Expert opinion on pharmacotherapy, 2011 - Taylor & Francis
Introduction: Alzheimer's disease (AD) is a daunting public health threat that has prompted
the scientific community's ongoing efforts to decipher the underlying disease mechanism …
the scientific community's ongoing efforts to decipher the underlying disease mechanism …
Alzheimer's disease: targeting the glutamatergic system
ME Conway - Biogerontology, 2020 - Springer
Alzheimer's disease (AD) is a debilitating neurodegenerative disease that causes a
progressive decline in memory, language and problem solving. For decades mechanism …
progressive decline in memory, language and problem solving. For decades mechanism …
Alzheimer's disease: An overview of amyloid beta dependent pathogenesis and its therapeutic implications along with in silico approaches emphasizing the role of …
M Awasthi, S Singh, VP Pandey, UN Dwivedi - Journal of the neurological …, 2016 - Elsevier
Alzheimer's disease (AD) is a progressive and irreversible neurodegenerative disorder
characterized by amyloid beta (Aβ) deposition in brain with subsequent formation of neuritic …
characterized by amyloid beta (Aβ) deposition in brain with subsequent formation of neuritic …
Multi-target drug candidates for multifactorial Alzheimer's disease: AChE and NMDAR as molecular targets
MS Uddin, A Al Mamun, MT Kabir, GM Ashraf… - Molecular …, 2021 - Springer
Alzheimer's disease (AD) is one of the most common forms of dementia among elder
people, which is a progressive neurodegenerative disease that results from a chronic loss of …
people, which is a progressive neurodegenerative disease that results from a chronic loss of …
Clinical trials of new drugs for Alzheimer disease: a 2020–2023 update
LK Huang, YC Kuan, HW Lin, CJ Hu - Journal of Biomedical Science, 2023 - Springer
Alzheimer's disease (AD) is the leading cause of dementia, presenting a significant unmet
medical need worldwide. The pathogenesis of AD involves various pathophysiological …
medical need worldwide. The pathogenesis of AD involves various pathophysiological …